Dark

Check out our Level2View

BIAFW
bioAffinity Technologies, Inc. Warrant
stock NASDAQ Warrant

At Close

Jul 23, 2026

0.00USD-100.000%(-0.09)1,000

0.00Bid 0.00Ask 0.00Spread

Pre-market

0.00USD-100.000%(-0.09)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsTrends

BIAFW Reddit Mentions

Subreddits

Limit Labels Price

We have sentiment values and mention counts going back to 2017. The complete data set is available via the API.

Take me to the API

BIAFW Specific Mentions

As of Aug 1, 2026 3:58:56 PM EDT (1 min. ago)

Includes all comments and posts. Mentions per user per ticker capped at one per hour.

293 days ago • u/Jackape5599 • r/pennystocks • whats_your_play_tomorrow_my_pick_is_biaf_it_has • :snoo_dealwithit: General Discussion :snoo_dealwithit: • B

119% float shorted and on threshold list. CTB over 690%. Float under 1 million. It’s at the very bottom price after RS and offering. Primed for a short squeeze.
Also, Q3 catalyst next month:
“10/07/2025 - 05:00 AM
SAN ANTONIO--(BUSINESS WIRE)-- bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today announced sales of its CyPath® Lung diagnostic test for lung cancer reached a new high in the third quarter of 2025, representing a 95% increase over the previous quarter. The increase reflects growing adoption by Veterans’ hospitals and market expansion in the mid-Atlantic region. In the first nine months of 2025, sales of CyPath® Lung rose 97% over the same period in 2024.”

sentiment -0.73

293 days ago • u/Jackape5599 • r/pennystocks • whats_your_play_tomorrow_my_pick_is_biaf_it_has • :snoo_dealwithit: General Discussion :snoo_dealwithit: • B

119% float shorted and on threshold list. CTB over 690%. Float under 1 million. It’s at the very bottom price after RS and offering. Primed for a short squeeze.
Also, Q3 catalyst next month:
“10/07/2025 - 05:00 AM
SAN ANTONIO--(BUSINESS WIRE)-- bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today announced sales of its CyPath® Lung diagnostic test for lung cancer reached a new high in the third quarter of 2025, representing a 95% increase over the previous quarter. The increase reflects growing adoption by Veterans’ hospitals and market expansion in the mid-Atlantic region. In the first nine months of 2025, sales of CyPath® Lung rose 97% over the same period in 2024.”

sentiment -0.73

Share